The research partnership between Tonix Pharmaceuticals and Columbia University in the US has been extended to serve the development of Covid-19 vaccines and therapies precision treatment techniques.
Additionally, Tonix Pharmaceuticals and Columbia University will analyse the immune responses of recovered or asymptomatic healthy subjects to Covid-19.
The partnership will also focus on in vitro T cell and antibody responses to the SARS-CoV-2 virus, which causes Covid-19.
The alliance intends to fill vital gaps in interpreting the detailed immune responses to Covid-19 and offer a base for customising vaccines and treatments to suitable people with precision therapeutic.
The researchers will evaluate the T cell and antibody responses in various ways, including at the cellular level by inducing T cells in vitro with CoV-2 antigens and by producing fully human monoclonal antibodies against SARS-CoV-2.
This study could lead to the isolation, characterisation and cloning of therapeutically significant fully human neutralising monoclonal antibodies to the virus.
Furthermore, the deoxyribonucleic acid (DNA) aptamer-based anti-idiotypes will be generated to specific monoclonal antibodies detected.
These aptamers could aid in identifying biomarkers for protective CoV-2 immunity and boost the design of precision medicine-driven Covid-19 vaccines.
Leave a Reply